Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial - Scorecard - MDSpire

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

  • By

  • Ghazaleh Tabatabai

  • Isabel Ramirez

  • Beatrix Welte

  • Paula Bombach

  • Hannes Becker

  • Denise Bernhardt

  • Regine Mayer-Steinacker

  • Friedegund Meier

  • Nicolas Neidert

  • Roland Roelz

  • Iris Mildenberger

  • Lukas Bunse

  • Michael Platten

  • Ulrich Herrlinger

  • Uwe M. Martens

  • Ulrike Ernemann

  • Manuela Neumann

  • Marcos Tatagiba

  • Lina Maria Serna-Higuita

  • Peter Martus

  • Mirjam Renovanz

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Intrathecal Administration of Nivolumab for Leptomeningeal Disease in Metastatic Solid Tumors: Dose Escalation Findings from the Multicenter IT-PD1/NOA-26 Phase 1 Study

At a Glance

CategoryDetail
Condition
Key MechanismsIntrathecal administration of nivolumab as an immune checkpoint inhibitor (source needed).
Target Population
Care Setting

Key Highlights

  • Remove unsupported phrases.

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • t
    • t
    • r
    • i
    • b
    • u
    • t
    • i
    • o
    • n
    • n
    • e
    • e
    • d
    • e
    • d
    • f
    • o
    • r
    • '
    • m
    • a
    • i
    • n
    • s
    • t
    • a
    • y
    • t
    • h
    • e
    • r
    • a
    • p
    • i
    • e
    • s
    • '
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with confirmed diagnosis of LMD and good-risk profile.

        Intrathecal nivolumab administered every 2 weeks for a total of six applications.

        Clinical Best Practices

        • remove

        Related Resources & Content

        Original Source(s)

        Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

        • by Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, Paula Bombach, Hannes Becker, Denise Bernhardt, Regine Mayer-Steinacker, Friedegund Meier, Nicolas Neidert, Roland Roelz, Iris Mildenberger, Lukas Bunse, Michael Platten, Ulrich Herrlinger, Uwe M. Martens, Ulrike Ernemann, Manuela Neumann, Marcos Tatagiba, Lina Maria Serna-Higuita, Peter Martus, Mirjam Renovanz

        • June 4, 2026

        Related Content

        Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

        Case Report: A rare case of over 45 years’ survival in a patient with tonsillar adenoid cystic carcinoma

        Disseminated hepatic epithelioid hemangioendothelioma with multiorgan metastases achieving long-term stability with Pazopanib: a case report